ASCO 2020：11项中华人民共和国研究入选口头报告，17项Poster报告

受全世界新冠疫情影响，原定于5月29日~6月2日在洛杉矶举行的美国药理学协才会（ASCO）讨论才会今年将首次以该线上形式承办，这是目前最大规模的该线上盛才会。今天，小组才会议的参考资料作文揭晓，共计103个sessions，当华南地区一共计11项研究工作入选为口头报告，17项入选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他埠头用以HER2+移出连续性乳腺肺癌（PHOEBE）：一项III期随机测试。

专场：移出连续性乳腺肺癌

笔记：当华南地区医学科学院的医院徐兵河系主任、马飞系主任，复旦大学除此以外的医院胡夕春系主任等

参考资料号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术后三阴连续性乳腺肺癌国际标准病患后卡培他埠头确保节拍疗程的III期测试（SYSUCC-001）。

专场：乳腺肺癌—暂时性/地带/主要用途病患

笔记：当浙江大学保健当区域内王树森系主任等

参考资料号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用移出连续性脑的表型特征来得出脑脊液当中循环DNA检测的概率: 新工具箱对抗老对手

专场：新工具箱解决老原因

笔记：李美芹 李温等

参考资料号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

了了非尼对布基纳法索拉非尼作为后期肠巨噬细胞肺癌的队内病患：一项对外开放标识、随机、多当区域内II/III期测试。

专场：小肠肠道肺癌—小肠冠状动脉、坏死和肠胆

笔记：四川大学华西的医院毕锋系主任、当解放军八一的医院秦叔逵系主任等

参考资料号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

当华南地区后期肠肺癌患儿阿帕替尼二该线病患：一项随机、安慰剂对照、双盲III期研究工作

专场：小肠肠道肺癌—小肠冠状动脉、坏死和肠胆

笔记：当解放军八一的医院秦叔逵系主任、四川大学华西的医院李秋系主任等

参考资料号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后期患连续性卵巢肺癌二次巨噬细胞减灭术的一项随机III期测试：SOC1 / SGOG-OV2。

不定期：针灸肺肺癌

笔记：复旦大学除此以外当中山的医院臧荣余系主任等

参考资料：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肺癌根治连续性子宫切除术后主要用途病患当中的序贯放疗程对比单独MRI或启动时放疗程（STARS研究工作）：一项随机、对照、对外开放标识的III期测试。

小组才会议：针灸肺肺癌

笔记：当浙江大学保健当区域内马尔季尼夫卡系主任、刘继红系主任等

参考资料号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：主要用途吉非替尼对比疗程用以可切除的EGFR变异的N1-N2期NSCLC-随机III期药理学测试的最终上都肉食动物归纳。

不定期：肺炎—非小巨噬细胞暂时性-地带/小巨噬细胞/其他颈部

笔记：广东省暴政的医院吴一龙系主任等

参考资料号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR变异俱移出非小巨噬细胞肺炎患儿队内色氨酸蛋白激酶抗病毒共计同或不共计同积极支部队暂时性MRI：III期对外开放标识药理学随机测试（SINDAS）的当末结果（NCT02893332）。

不定期：肺炎-非小巨噬细胞移出

笔记：贵州省暴政的医院曾铭系主任等

参考资料：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对更进一步丧生-1（PD-1）的人源化IgG4酵母共计同阿昔替尼用以移出连续性黏膜黑色素遗传性患儿的Ib期研究工作的总肉食动物期和海洋生物标志物归纳。

不定期：黑色素遗传性/皮肤肺癌

笔记：北京师范大学的医院郭军、盛锡楠系主任等

参考资料：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全连续性和结果：共通CAR-T巨噬细胞首次消化系统测试病患患/难治连续性T巨噬细胞急连续性淋巴巨噬细胞前列腺肺癌（r/r T-ALL）的安全连续性和。小组才会议：研发当中的病患技术-免疫病患。笔记：王欣欣等参考资料：3013贴纸：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后期冠状动脉柱状巨噬细胞肺癌患儿当中的应用领域：一项随机的对外开放标识II期测试（ORIENT-2）。小组才会议：小肠肠道肺癌-小肠冠状动脉肺癌、坏死肺癌和肠胆道肺癌笔记：徐建明系主任等参考资料：4511贴纸：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异连续性CAR-T巨噬细胞对髓母巨噬细胞遗传性的禁绝连续性病患小组才会议：当血清素笔记：代红久、孙斌、杨东、徐晖、邵小金、魏佳、邵旭东参考资料：2522贴纸。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后期错配修复缺陷患儿当中的应用领域小组才会议：研发当中的病患学-免疫病患笔记：沈琳系主任等参考资料：3021贴纸。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 继发性CD7-CART病患患/难治连续性ACUTE淋巴巨噬细胞前列腺肺癌/淋巴遗传性的首例消化系统药理学测试小组才会议: 研发连续性病患学-免疫病患笔记简介：张明志，杨林等参考资料：3026贴纸: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 昂替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度醯（T）共计同引入后期实质遗传性患儿的Ib期研究工作小组才会议：发展连续性病患学--分子载体口服和海洋生物学笔记：龚继芳，沈琳系主任等参考资料：3523贴纸：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin共计同抗肺癌口服和nedaplatin病患患连续性或移出连续性冠状动脉柱状巨噬细胞肺癌（ESCC）患儿的II期研究工作。小组才会议：小肠肠道肺癌-小肠冠状动脉、坏死和肠胆道肺癌的研究工作笔记：王志强劲，李玉红，王德申，王凤华，任超，谭琼 王志强劲、李玉红、王德深、王凤华、任超、谭琼参考资料：4522贴纸：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.小组才会议：小肠肠道肺癌-小肠冠状动脉肺癌、坏死肺癌和肠胆管肺癌的二该线病患笔记：宋艳等参考资料：4524贴纸：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种血液外体马蹄形RNA该线性系统用以初始组织学时检测高等级肺癌的血液外体马蹄形RNA该线性系统：一项多当区域内的回顾连续性研究工作小组才会议：泌尿上皮细胞肺肺癌---肺癌、睾丸肺癌和肺癌笔记简介：Liaoyuan Li等参考资料：5522贴纸。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 暂时性后期宫颈肺癌都将疗程后的主要用途疗程小组才会议: 针灸肺肺癌笔记简介： 李珉珉等参考资料：6031贴纸：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病患甲状腺髓连续性肺癌的相关连续性：基于ALTER01031测试的归纳。才会话：头颈部笔记：天津市的医院擅长于系主任参考资料：6526贴纸。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼病患后患儿上集的影响: ALTER01031的亚组归纳小组才会议：头颈部笔记：天津市的医院擅长于系主任参考资料：6527贴纸。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA归纳得出I-IIIA期非小巨噬细胞肺炎（NSCLC）患儿术后患: GASTO1035和GASTO1018的结果小组才会议：肺炎-非小巨噬细胞暂时性-地带连续性/小巨噬细胞/小巨噬细胞/其他胸科肺肺癌笔记：Si-Yu Wang等参考资料：9023贴纸：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞肺炎（NSCLC）当中EGFR色氨酸蛋白激酶抗病毒的新型耐药机制小组才会议:肺炎-非小巨噬细胞移出连续性肺炎笔记简介：邵昕，金小妹，满宇，欧秋香，华宝，薛武，杨少，范敏 邵昕、金小妹、满宇、欧秋香、华宝、薛武、杨绍、范敏参考资料：9528贴纸：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1测试当中后期黑色素遗传性总肉食动物的替代终点小组才会议：黑色素遗传性/皮肤肺癌笔记：聂润聪，袁书强劲，李元芳，陈英波，周志伟 聂润聪、袁书强劲、李元芳、陈英波、周志伟参考资料：10030贴纸：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病患患或移出连续性原发连续性恶连续性骨患儿的II期研究工作小组才会议： 肉遗传性笔记：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、曹吉祥、蔡启庆、涂崇奇、范正福、杨瑶参考资料：11525贴纸。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步口碑安罗替尼在后期肉遗传性患儿多该线病患当中的安全连续性和。小组才会议：肉遗传性笔记：姚伟涛，王家强劲，周明，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王家强劲、周明、王鑫、杜鑫辉、田志超、牛晓英参考资料：11526贴纸：414